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Abstract 
The objective of this study is to choose the best methodology containing a high-efficiency extraction technique and an 
extraction agent for the isolation of antidepressants, such as citalopram, fluoxetine, paroxetine, sertraline, and venlafaxine, 
from human blood samples. In this research, various extraction agents have been examined to achieve the highest efficiency 
of the conducted process. Moreover, the following most available extraction techniques have been investigated and com-
pared: liquid–liquid extraction, ultrasound-assisted extraction, and microwave-assisted extraction. The obtained extracts 
have been analysed with the application of the ultra-high performance liquid chromatography with mass spectrometry. The 
conducted research has confirmed that the microwave-assisted extraction with ethyl acetate—the average extraction effi-
ciency is 77.4 ± 2.7%—onstitute the most promising extraction method and the agent. Furthermore, the developed method 
was successfully applied to the analysis of the whole blood samples collected from patients treated with the analysed drugs. 
It should be emphasised that choice of extraction and solvent methods are the first steps to develop the methods allowing for 
determination of antidepressants in whole blood for toxicological and clinical purposes.
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Introduction
Selective serotonin reuptake inhibitors (SSRI) are the first-
line antidepressants, applied in the treatment of mood dis-
order. They are called selective because they seem to affect 
primarily serotonin, not other neurotransmitters. Their main 
mechanism of action is to inhibit the reabsorption (reuptake) 
of serotonin. All drugs in this group work in a similar way 
and they can cause similar side effects, despite better overall 
safety and tolerability in comparison to older antidepres-
sants. Due to their positive properties and high treatment 
effectiveness as regards patients with mood disorder, the 
most frequently used ones include citalopram, fluoxetine, 
paroxetine, and sertraline [1–6].
There is a drug similar to SSRIs in terms of both desired 
and side effects—venlafaxine. It belongs to the seroto-
nin–norepinephrine reuptake inhibitors (SNRI). In spite of 
this, the effect of venlafaxine at low doses is significantly 
lower on norepinephrine than on serotonin. It is also one 
 * Magdalena Świądro 
 magda.swiadro@doctoral.uj.edu.pl
1 Department of Analytical Chemistry, Faculty of Chemistry, 
Jagiellonian University in Kraków, Kraków, Poland
2 Department of Adult Psychiatry, Jagiellonian University 
Medical College in Kraków, Kraków, Poland
1226 M. Świądro et al.
1 3
of the most popular antidepressant used in the treatment of 
mood disorder [7, 8]. The selected properties of SSRIs and 
SNRIs are presented in Table 1.
The SSRIs and SNRIs are the most used antidepres-
sants. Their efficacy after administration as first-line drugs 
is approximately 60%, where only 15% of patients do 
not achieve remission after several subsequent treatment 
attempts (STAR-D study) [9, 10]. One of the most signifi-
cant reasons for the lack of response to treatment is poor 
collaboration, which results in a lack of adequate drug levels. 
Individual differences in drug metabolism may also play an 
important role here [11]. Hence, it is crucial to control the 
concentration of these drugs in biological material. New 
methods are still being sought for determining the concen-
tration of medicines, which would facilitate the therapeutic 
drug monitoring of the patient. It is useful for better adjust-
ment of doses to the treatment of an individual patient. 
Nevertheless, the extraction procedure is the main step in 
the analysis of human fluids and tissues. If the extraction 
efficiency is high, it guarantees the proper isolation of drugs 
and, consequently, accurate results. What is more, the extrac-
tion technique should be accordance with the principles of 
green analytical chemistry. Within this green extraction con-
cept, an extract should be obtained in such a way to have 
the lowest possible impact on the environment. Armenta 
et al. [14] suggest remarking the green extraction aspects of 
the currently used methods based on miniaturization, auto-
mation, voiding the use of single-use plastic consumables, 
reducing exploration costs, and avoiding toxic residues accu-
mulation. Due to this, each proposed methodology applied 
for determination and isolation of SSRIs and SNRIs drugs 
must be more innovative, ecologic, and economic [12–14].
Some of the most frequently used and available tech-
niques for isolation analytes from biological material include 
liquid–liquid extraction (LLE), ultrasonic-assisted extraction 
(UAE), and microwave-assisted extraction (MAE). However, 
each of these techniques has both its advantages and disad-
vantages. The LLE extraction is characterized by simplicity, 
universality, and it does not require expensive apparatus. 
Remane et al. [15] described LLE extraction as a fast and 
simple procedure used for analyzed drugs from different 
classes. The wide range of different classes covered with 
acceptable results for 119 analytes, including SSRIs and 
SNRIs drugs, constitutes the major advantage and novelty. 
Unfortunately, the LLE extraction has disadvantages as well. 
For example, it often produces an emulsion that is difficult 
to remove or separate [15, 16].
Nowadays, extraction methods seek an increase in extrac-
tion yield and reproducibility of operations, and the reduc-
tion of extraction time and solvent consumption, which 
implies a significant improvement in cost saving and envi-
ronmental benefits. Thus, LLE extraction is gradually being 
replaced in analytical laboratories by UAE and MAE tech-
niques [12, 14]. Both UAE and MAE are easy to handle, 
safe, and economical. They constitute automated extraction 
technique where it is possible to control the extraction time 
and temperature. Moreover, they are the optimal technique 
for thermolabile compounds, where at the same time, it is 
possible to prepare multiple (up to 40) samples. The appli-
cation of the microwave-assisted extraction as an isolation 
technique provides a significant decrease in the required time 
of extraction as suggested by Wietecha-Posłuszny et al. [17], 
who have used MAE extraction in a new screening method-
ology for the identification of 30 psychoactive drugs, includ-
ing antidepressants [8, 17, 18].
There are numerous publications on the extraction of anti-
depressants from biological material using more advanced 
(sometimes more expensive) extraction techniques such as 
solid-phase microextraction procedure [19], protein precipi-
tation [6], or dispersive liquid–liquid microextraction [18]. 
However, not every laboratory can afford to use modern 
techniques. Therefore, the aim of the research has been to 
select the most effective first-line extraction method—among 
LLE, UAE, and MAE extraction techniques—that is useful 
to isolate antidepressants from SSRI and SNRI groups from 
whole blood. The crucial element was to choose an optimal 
extraction agent for extraction citalopram, fluoxetine, par-
oxetine, sertraline, and venlafaxine. The research allows to 
uniquely choose high-efficiency extraction technique char-
acterized by its simplicity, automation, and environmental 
friendliness. Furthermore, the suggested methodology has 
been applied to the analysis of real blood samples taken from 
patients with a mood disorder. This was a group of patients 
(female and male at different ages) treated with SSRIs or 
SNRIs drugs.
Results and discussion
Selection of extraction agent and technique
In the case of extraction from whole blood, no obvious state-
ments may be made as to which extraction technique and 
Table 1  Selected properties of selective serotonin reuptake inhibitors 
and serotonin norepinephrine reuptake inhibitors drugs





9.50 3.74 325.171 ± 0.001
Fluoxetine 10.3 4.05 310.141 ± 0.001
Paroxetine 9.90 3.95 330.150 ± 0.001





10.1 3.28 278.212 ± 0.001
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agents are excellent for SSRIs and SNRIs drugs. The aim 
of this stage was to select the extraction agents which tested 
compounds, extracted from the blood in undissociated form, 
passing more efficiently to the organic phase, as a result. 
Due to these different extraction agents such as: chloroform, 
hexane, ethyl acetate, ethyl acetate: hexane (10:90, v/v) 
methyl alcohol: acetonitrile (1:1, v/v), and 3-methylbutan-
1-ol: hexane (1:99, v/v) were selected and compared. Each 
solvent was tested using three extraction techniques: LLE 
(extraction parameter: 10 min), UAE (extraction parameters: 
10 min, 25 °C), and MAE (extraction parameters: 10 min, 
50 °C, 800 W). The samples were prepared according to the 
procedure described in the section “Sample preparation”, 
at the drug concentration 500 ng/cm3. Moreover, for each 
sample, 0.6 M NaOH (pH = 13.5) was added. Under these 
conditions, the pH value is higher than the pKa value of the 
analysed drugs (see Table 1). The formation of a strongly 
alkaline environment during the extraction resulted in the 
citalopram, fluoxetine, paroxetine, sertraline, and venlafax-
ine being mostly in uncharged form, and thus showing a 
greater affinity for the organic phase.
In the preliminary research, two of them (chloroform and 
methyl alcohol: acetonitrile) were rejected due to a problem 
in a blood preparation step where observed the protein pre-
cipitation (coagulation) which prevented further analysis. 
Therefore, in the further analysis, only hexane, ethyl acetate, 
ethyl acetate: hexane (10:90, v/v), and 3-methylbutan-1-ol: 
hexane (1:99, v/v) were used. Each time, three samples were 
prepared and analysed three times using UHPLC-MS tech-
nique. The results were compared by means of the extraction 
efficiency (EE) relating to an analyte. It was calculated as 
regards, the ratio of the relative peak area obtained for an 






 in comparison to the relative 







The obtained extraction efficiency of citalopram, fluox-
etine, paroxetine, sertraline, and venlafaxine isolated from 
whole blood with the use of the LLE, UAE, and MAE 
extraction and various extraction solvents, have been sum-
marized in Table 2.
As can be seen, each solvent extracted all investigated 
antidepressants; however, their optimum extraction param-
eters are completely different. For instance, citalopram, ser-
traline, and venlafaxine are best when extracted in the mix-
ture consisting of 3-methylbutan-1-ol and hexane (1:99, v/v), 
in contrast to fluoxetine that is best isolated with application 
of hexane. In the case of paroxetine, the best efficiency was 
obtained using ethyl acetate. Moreover, the extraction effi-
ciency (see Table 2) in the same extraction agent is different 
for the analysed extraction techniques. For example, taking 
into consideration the LLE extraction and UAE extraction, 
the best results were obtained using 3-methylbutan-1-ol: 
hexane, yet, higher performance was obtained for UAE—
the EE = 50.9 ± 4.9 for LLE and EE = 63.9 ± 1.9 for UAE. 
It was observed that ethyl acetate allows for achievement 
of the best extraction efficiency (EE = 77.4 ± 2.7) with the 
application of MAE extraction. Both SSRIs and SNRIs 
have satisfactory EE, which is certainly due to the character 
of the performed process, as the action of the microwave 
prompts the destruction of the blood cells (from the inside). 













Table 2  Summary of the extraction efficiency obtained based on the liquid–liquid extraction (LLE), ultrasonic-assisted extraction (UAE), and 
microwave-assisted extraction (MAE) techniques and different extraction agents
Extraction 
technique
Extraction agent Extraction efficiency (EE) /% (n = 5) Average extraction 
efficiency ( 
−
EE)/%Citalopram Fluoxetine Paroxetine Sertraline Venlafaxine
LLE Hexane 33.0 ± 6.7 38.4 ± 3.4 58.5 ± 9.6 38.4 ± 1.9 40.1 ± 1.3 41.7 ± 4.6
Ethyl acetate 30.2 ± 2.5 35.4 ± 2.1 25.8 ± 1.7 29.8 ± 3.2 38.3 ± 1.1 31.9 ± 3.9
Ethyl acetate: hexane (10:90, v/v) 50.9 ± 4.8 45.1 ± 3.3 48.6 ± 5.9 51.3 ± 1.2 47.2 ± 5.4 48.6 ± 4.2
3-Methylbutan-1-ol: hexane (1:99, v/v) 81.0 ± 3.8 36.0 ± 5.4 30.1 ± 6.0 38.1 ± 5.2 69.4 ± 4.0 50.9 ± 4.9
UAE Hexane 47.2 ± 2.9 23.9 ± 0.4 76.6 ± 1.4 57.0 ± 2.1 18.0 ± 1.3 44.5 ± 1.6
Ethyl acetate 56.3 ± 2.0 28.6 ± 1.1 13.6 ± 3.7 68.2 ± 0.8 24.5 ± 0.6 38.2 ± 1.4
Ethyl acetate: hexane (10:90, v/v) 26.5 ± 2.1 78.9 ± 2.1 19.7 ± 3.7 49.7 ± 1.9 69.3 ± 2.9 48.9 ± 2.5
3-Methylbutan-1-ol: hexane (1:99, v/v) 62.4 ± 2.1 59.1 ± 1.3 44.2 ± 3.7 90.4 ± 0.3 63.2 ± 2.4 63.9 ± 1.9
MAE Hexane 26.9 ± 5.9 84.9 ± 2.2 34.0 ± 1.3 71.9 ± 1.4 76.4 ± 0.9 58.8 ± 2.3
Ethyl acetate 60.8 ± 3.2 81.4 ± 2.4 79.4 ± 1.8 77.2 ± 1.9 88.4 ± 4.3 77.4 ± 2.7
Ethyl acetate: hexane (10:90, v/v) 54.1 ± 1.2 73.2 ± 5.0 47.3 ± 2.7 56.9 ± 4.9 59.5 ± 2.2 58.2 ± 3.2
3-Methylbutan-1-ol: hexane (1:99, v/v) 57.2 ± 2.3 81.0 ± 1.5 65.7 ± 3.6 73.8 ± 2.6 91.9 ± 3.7 73.9 ± 2.6
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acetate—may be successfully used in clinical patients’ blood 
samples. Moreover, the suggested methodology constitutes 
a good alternative to fast, easier and cheaper method of the 
drugs employed in clinical examinations. In addition, it may 
be useful for comparison with novel extraction techniques.
Validation procedure
The validation procedure of the suggested extraction meth-
odology was carried out according to the literature guide-
lines [8, 20]. Validation parameters, such as linearity, the 
limit of detection (LOD), the limit of quantitation (LOQ), 
and precision (CV) obtained with the application of the 
microwave-assisted extraction method and ethyl acetate as 
the extraction agent are presented in Table 3.
The linearity of the optimized method was tested in the 
range with concentration points: 25, 50, 100, 150, 200, 
250, and 300 ng/cm3, for each of the drugs. Calibration 
curves were based on a linear regression model that took 
into account the ratio of the peak area of each compound to 
that of the IS. Deuterated compounds from the same groups 
of drugs as the studied compounds, such as fluoxetine-D5 
for fluoxetine and sertraline, paroxetine-D5 for paroxetine 
and citalopram, and venlafaxine-D5 for venlafaxine, were 
used. The concentration of each IS (added to the samples 
before the extraction process) was constant and amounted 
to 150 ng/cm3.
The limits of detection (LOD) and quantification (LOQ) 
were calculated as the ratios of three times and ten times 
the standard deviation of the analytical signal measured 
at 50 ng/cm3 to the slope of the calibration graph, respec-
tively. The calculated LOD and LOQ values indicate the 
possibility of determining the studied compounds at the low 
concentration.
As for precision, this was determined at medium (150 mg/
dm3) levels. For intraday precision (n = 9), three samples 
containing analytes of the concentration were analysed and 
each analysis was repeated three times. The interday pre-
cision (n = 27) was evaluated by repeating the analysis for 
three consecutive days. The obtained results confirm that 
for analysed drugs, the intraday precision was lower than 
9.6% and interday precision was lower than 13.7% for each 
analyte. It is in accordance with the accepted criteria (see 
Table 3)—less than ± 15.0% [20]. Moreover the obtain preci-
sion was similar to isolation of SSRIs and SNRIs with the 
application of the novel extraction techniques—dispersive 
liquid–liquid microextraction [18], which further empha-
sizes the possibility of using traditional MAE extraction. 
The obtained results were better than protein extraction to 
determine sertraline. The intraday precision of the developed 
method was lower than 12% [21].
The satisfying results for validation of the proposed meth-
odology of isolation of citalopram, fluoxetine, paroxetine, 
sertraline, and venlafaxine from whole blood using the 
MAE extraction and ethyl acetate guarantee the possibility 
of its application for the analysis of the blood samples of 
the patients.
Case samples
The validated method based on the combination of MAE 
extraction and ethyl acetate (such as extraction agent) was 
applied for the analysis of real samples collected in vivo. 
The clinical samples were provided by the Department of 
Adult Psychiatry at the Jagiellonian University Medical Col-
lege. The whole blood samples were collected from patients 
treated by SSRIs and SNRIs drugs. The first patient (case 
#I) was a 61-year-old male treated with 150 mg of prefax-
ine (venlafaxine). Case #II (51-year-old male), case #IV 
(41-year-old male) and case #V (47-year-old female) were 
treated with 75 mg of effectin ER (venlafaxine). Case #III 
was collected from a female who was treated with 20 mg 
parogen (paroxetine). Each patient suffered from a mood dis-
order—bipolar disorder or depression. The obtained results 
are presented in Table 4.
As can be seen in Table 4, in each case #I–V samples 
were successfully used in identifying the analysed drugs 
in therapeutic concentration—paroxetine in the range 
10–75 ng/cm3 and venlafaxine 250–750 ng/cm3 [22].On 
this basis, it can be concluded that the patient takes this 
Table 3  Validation parameters 
obtained with the application 
of the microwave-assisted 
extraction method and ethyl 
acetate as the extraction agent
Parameter Results
Citalopram Fluoxetine Paroxetine Sertraline Venlafaxine
Linearity range/ng/cm3 LOQ-300
R2 0.9902 0.9876 0.9708 0.9820 0.9886
Slope 0.0044 0.0010 0.0014 0.0023 0.0175
LOD/ng/cm3 4.1 ± 2.0 4.6 ± 5.0 3.6 ± 4.3 3.7 ± 4.1 1.8 ± 0.6
LOQ/ng/cm3 13.5 ± 6.6 15.3 ± 6.7 11.9 ± 3.8 12.3 ± 3.5 5.9 ± 2.0
Precision, CV/%
 Intraday (n = 9) 6.8 4.7 9.6 7.9 8.6
 Interday (n = 27) 10.6 8.8 13.7 11.6 9.8
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medication according to the psychiatrist’s recommendation. 
It may be a good preliminary step to develop the analytical 
and quantitative research for a larger group of drugs.
Conclusion
In the proposed research, three most common extraction 
techniques—LLE, UAE, and MAE extraction have been 
compared. The main goal was to choose the easiest and high-
efficiency methodology for isolation of SSRIs and SNRIs 
drugs from human blood. As it has been presented, the best 
results are obtained by means of the ethyl acetate in conjunc-
tion with MAE extraction. Moreover, the suggested MAE 
extraction technique is rapid and easy to handle as well as it 
moderates solvent consumption. It enables the isolation of 
drugs with high efficiency, which is important in qualitative 
analysis. The results of the analyses of real samples indicate 
the possibility of using the suggested methodology based 
on the combination of MAE extraction and ethyl acetate for 
the isolation of SSRIs and SNRIs drugs from blood. It may 
prove to be a useful contribution to development of the new 
methods for therapeutic drug monitoring (i.e., patients with 
depression) or in forensic and toxicology analysis.
Experimental
Chemicals and materials
Drug standards and their deuterated analogue at a concen-
tration of 1 mg/cm3: citalopram, fluoxetine, paroxetine, 
sertraline, venlafaxine, fluoxetine-D5, paroxetine-D5, and 
venlafaxine-D5 were purchased from Lipomed AG (Switzer-
land). Each standard solution was stored in methyl alcohol 
in a freezer at − 20 °C. The other chemicals used throughout 
the experiments, such as: chloroform, formic acid, hexane, 
acetic acid, and sodium tetraborate decahydrate (borax), 
were purchased from Sigma-Aldrich (USA). Acetonitrile, 
3-methylbutan-1-ol, and methyl alcohol were supplied by 
Fluka Analytical (Germany), whereas the 3-methylbutan-
1-ol was obtained from Chempur (Poland). Ethyl acetate 
was purchased from Avantor Performance Materials 
POCH (Poland). Ultrapure water (18.2 MΩ cm, < 3 ppb 
TOC) which was used to prepare all aqueous solutions was 
generated with the Milli-Q system by Merck-Millipore 
(Darmstadt, Germany).
Instrumentation
The measurements were carried out using UltiMate 3000 
RS liquid chromatography system (Dionex, USA) coupled 
with a mass spectrometer MicrOTOF-Q II with a time of 
flight mass analyser (Bruker, Germany). The mobile phase 
consisted of 0.1% formic acid in ultrapure water (A) and 
acetonitrile (B). The following gradient programme (B) at 
the flow rate of 0.4 cm3/min was used: 0 min − 5%; 14 min 
− 70%; 16.5 min − 5%; 20 min − 5%. Separation was car-
ried out in a Hypersil Gold Phenyl column (50 mm × 2.1 mm 
I.D., particles 1.9 μm, injection: 5 mm3, Dionex) at 20 °C. 
The ESI ion source conditions were as follows: nebulizer 
pressure: 2.5 bar, dry gas: 5.5 dm3/min heated to 200 °C. 
Data were recorded in the positive ion mode and profile 
spectra were acquired in the mass range 100–1000 m/z. 
Cluster mass calibration was performed using a mixture of 
10 mM sodium formate and isopropanol before each run.
For the extraction of drugs from human blood ultrasonic 
bath SONIC-3 (Polsonic, Poland), which works at the fre-
quency of 40 kHz. and a MARS 5 microwave-assisted sam-
ple preparation system (CEM Matthews NC, USA) equipped 
with 24 Xpress PHA vessels (75  cm3) were used.
Blood collections
In the present study, whole human blood (drug free) was 
provided by at local blood bank (Krakow, Poland). The 
real case samples from patients (case #I–V), who took the 
analysed drugs were kindly provided by the Department of 
Adult Psychiatry at the Jagiellonian University Medical Col-
lege (according to the Bioethical Commission Approval no 
1072.6120.302.2018). All the samples were stored at the 
temperature of − 20 °C prior to the analysis in accordance 
with the standard laboratory practice.
Sample preparation
The solutions of citalopram, fluoxetine, paroxetine, sertra-
line, and venlafaxine were prepared at a concentration of 
100 ng/cm3 in methyl alcohol with the application of stock 
solutions at a concentration 1 mg/cm3. Subsequently, it 
Table 4  Results obtained from 
analysis of real case samples
Parameters Case #I Case #II Case #III Case #IV Case #V
Drug Venlafaxine Venlafaxine Paroxetine Venlafaxine Venlafaxine
tR/min 3.84 ± 0.01 3.85 ± 0.01 6.23 ± 0.01 3.84 ± 0.01 3.88 ± 0.02
Final concentra-
tion/ng/cm3
287.5 ± 2.3 386.3 ± 2.0 54.6 ± 1.3 406.8 ± 3.1 265.2 ± 1.6
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evaporated under nitrogen at the temperature of 40 °C. Then, 
300  mm3 of whole blood and 300  mm3 of borate buffer 
(pH = 9.5) were added to each probe and vortexed (Vortex 
Heidolph, Germany) for 5 min. The prepared samples were 
extracted using three techniques—LLE, UAE, and MAE—
and for testing six different extraction solvents: chloroform, 
hexane, ethyl acetate, ethyl acetate: hexane (10:90, v/v), 
methyl alcohol: acetonitrile (1:1, v/v), and 3-methylbutan-
1-ol: hexane (1:99, v/v). The amount of 1  cm3 of extraction 
solvent (during analyses) was added and these prepared sam-
ples were gently agitated for 10 min using at platform shaker 
(LLE) or sonicated for 10 min at 25 °C (UAE). The MAE 
extraction was performed with the application of 3  cm3 of 
extraction solvent using the following parameters: 10 min, 
50 °C and 800 W. Next, for each sample, the amount of 1 
 cm3 of 0.6 M NaOH was added, then vortexed for 2 min and 
filtrated using PTFE filters (0.25 μm). Finally, the superna-
tant was transferred to a new probe and evaporated under 
nitrogen. Prior to UHPLC-MS analysis, 100  mm3 of mobile 
phase (acetonitrile 0.1% formic acid, 1:9, v/v) was added.
In respect of case #I–V samples, 300  mm3 of whole 
blood was taken and 300  mm3 of borate buffer was added 
(pH = 9.5). The prepared samples were extracted using only 
the MAE technique (10 min, 50 °C, and 800 W) and ethyl 
acetate as an extraction agent. Other activities were carried 
out analogically as described above.
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